Howe & Rusling’s Heron Therapeutics HRTX Stock Holding History

Howe & Rusling’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-50	Closed	–	–	1118
2022 Q2	$0	Buy	+50	New	+$201	﹤0.01%	1105

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Howe & Rusling's HRTX Position: Q3 2022 in Review

Howe & Rusling sold out of Heron Therapeutics (HRTX) in Q3 2022, closing a stake of 50 shares.

Howe & Rusling first reported a position in HRTX in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 186 funds tracked by Wall St. Rank hold HRTX as of Q3 2022.

Howe & Rusling reported no remaining Heron Therapeutics position as of Q3 2022 after selling out during the quarter.
Howe & Rusling sold 50 Heron Therapeutics shares in Q3 2022.
Howe & Rusling first reported a position in Heron Therapeutics in Q2 2022 and held it in 1 quarter.
Howe & Rusling's Heron Therapeutics position peaked at $0 in Q2 2022.
186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2022.

Based on Howe & Rusling's 13F filing for Q3 2022, filed 14 Nov 2022.